Carmignac Gestion Incyte Corp Transaction History

Carmignac Gestion

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $68.3 Million - $94.8 Million	-1,074,714 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $976,950 - $1.17 Million	-16,700 Reduced 1.53%	1,074,714 $68.3 Million
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $290,225 - $348,881	-4,700 Reduced 0.43%	1,091,414 $75.4 Million
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $529,395 - $730,626	8,700 Added 0.8%	1,096,114 $73.4 Million
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $9.83 Million - $11.9 Million	118,299 Added 12.21%	1,087,414 $90.6 Million
Q4 2017 Feb 13, 2018	BUY	$93.56 - $116.6 $90.7 Million - $113 Million	969,115	969,115 $91.8 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.